Peter H Addy's Avatar

Peter H Addy

@peterhaddyphd.bsky.social

Educator, psychotherapist, clinical supervisor.

10 Followers  |  13 Following  |  12 Posts  |  Joined: 22.05.2025  |  1.6311

Latest posts by peterhaddyphd.bsky.social on Bluesky

How do you think this approval affects the broader ketamine therapy landscape? Should generic ketamine have similar approval pathways?

06.06.2025 18:11 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0

This creates a two-tier system: expensive pharmaceutical esketamine for those with insurance coverage, and cash-pay ketamine clinics for everyone else. The same molecule, different access points, vastly different costs.

06.06.2025 18:11 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 1    πŸ“Œ 0

But here's the contradiction: while esketamine requires certified facilities and strict monitoring, generic ketamine operates in a regulatory gray zone. The FDA warns about unmonitored compounded ketamine use, yet the approval pathway for generic ketamine remains unclear.

06.06.2025 18:11 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 1    πŸ“Œ 0

This represents a significant shift in how regulators view psychedelic medicines - acknowledging they can be primary treatments, not just last resorts. About a third of adults don't respond to oral antidepressants alone.

06.06.2025 18:11 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 1    πŸ“Œ 0
Post image Post image Post image Post image

The FDA just expanded approval for Johnson & Johnson's Spravato (esketamine) nasal spray, allowing it to be used as a standalone treatment for severe depression rather than only as an add-on to traditional antidepressants.

06.06.2025 18:11 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 1    πŸ“Œ 0

But geography, cost, and regulatory barriers still determine who gets help.

What questions do you think Oregon's upcoming research should prioritize? How do we learn from these 8,000 experiences to expand access nationwide?

04.06.2025 17:10 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0

But the bigger story here is about access and equity. Most service centers cluster near Interstate 5, leaving eastern Oregon underserved. Here's what this tells us about the economic structures shaping psychedelic access: when we create legal pathways, demand is enormous.

04.06.2025 17:10 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 1    πŸ“Œ 0
Post image Post image Post image Post image

Oregon's psilocybin services just hit a remarkable milestone: 8,000 people have completed therapy sessions in the state's first full year of operation. That's 3 times more than all previous psilocybin clinical trials combined. With only 5 emergency calls, the safety profile is impressive.

04.06.2025 17:10 β€” πŸ‘ 1    πŸ” 0    πŸ’¬ 1    πŸ“Œ 0

The challenge is holding space for the transpersonal while maintaining clinical grounding and safety.

What's your experience working with transpersonal material in therapy?

02.06.2025 16:09 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0

Traditional therapy models don't always have language for these phenomena. Transpersonal psychology gives us tools to:
- Normalize these experiences
- Integrate them therapeutically
- Support clients in making meaning
- Bridge personal healing with larger purpose

02.06.2025 16:09 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 1    πŸ“Œ 0

This framework acknowledges that psychological wholeness often involves connection to community, nature, spirituality, or universal consciousness. In psychedelic work, clients frequently report experiences of ego dissolution, unity consciousness, or profound spiritual insights.

02.06.2025 16:09 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 1    πŸ“Œ 0
Post image Post image Post image Post image

Transpersonal psychology provides a crucial framework for understanding what happens in psychedelic therapy when clients report experiences beyond their ordinary sense of self. Rather than pathologizing these experiences, transpersonal approaches recognize them as potentially healing and meaningful.

02.06.2025 16:09 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 1    πŸ“Œ 0

@peterhaddyphd is following 13 prominent accounts